

March 30, 2026

Attn: House Committee on Health and Human Services
RE: Support for House Bill H 8318

Dear Chair Donovan and distinguished members of the House Committee on Health and Human Services:

My name is Camille Williams, and I am a Certified Nurse-Midwife from Providence. I have been a prescribing reproductive health care provider in Rhode Island for 18 years, now specializing in menopausal and perimenopausal hormone therapy. I am a Menopause Society Certified Practitioner (MSCP) through The Menopause Society (formerly the North American Menopause Society).

I am writing in support of House Bill H8318, which would remove the requirement for testosterone prescriptions to be reported to the Prescription Drug Monitoring Program. There is no evidence to support testosterone's inclusion with medications that cause substance use disorders. Naming patients who receive testosterone prescriptions in a database is unnecessary and invasive, without attending potential for benefit or risk reduction.

I prescribe testosterone therapy to women in appropriate low doses to treat hypoactive sexual desire disorder (low libido). This is an evidence-based use of transdermal testosterone supported by The Menopause Society, The International Society for the Study of Women's Sexual Health, the International Menopause Society, The European Menopause and Andropause Society and others. There is no need or benefit to reporting my patients' testosterone prescriptions to the PDMP.

While transgender patients are not currently part of my patient population, I support House Bill 8318 on their behalf as well. Considering the discrimination this community faces within the medical system and society at large, it is especially important to avoid unnecessary reporting to data bases to preserve their privacy and anonymity.

Thank you for your consideration and please support House Bill 8318.

Regards,

Camille Williams, CNM, MSCP
53 Hillside Ave
Providence, RI 02906